Literature DB >> 8175679

Contribution of the C-terminal domain of metalloproteinases to binding by tissue inhibitor of metalloproteinases. C-terminal truncated stromelysin and matrilysin exhibit equally compromised binding affinities as compared to full-length stromelysin.

V M Baragi1, C J Fliszar, M C Conroy, Q Z Ye, J M Shipley, H G Welgus.   

Abstract

In this study, we have used high resolution gel-filtration chromatography and measurements of Ki to compare the capacity of full-length native stromelysin, C-terminal truncated stromelysin (Phe100-Pro273), and matrilysin (the only metalloproteinase spontaneously lacking a C-terminal hemopexin-like domain) to bind to the tissue inhibitor of metalloproteinases (TIMP). While prostromelysin failed to bind TIMP, active stromelysin bound to the inhibitor avidly, exhibiting an affinity for TIMP (Ki = 8.3 x 10(-10) M) essentially identical to that of active interstitial collagenase as determined by competition experiments. C-terminal truncated stromelysin also formed a higher M(r) complex with TIMP which survived gel filtration. However, when truncated stromelysin was forced to compete with its full-length parent molecule for limiting amounts of TIMP, the full-length enzyme preferentially bound to the inhibitor. Indeed, binding studies indicated a Ki of 5.95 x 10(-9) M for the truncated variant's interaction with TIMP, only 14% as tight as that of full-length stromelysin. We also examined the interaction between TIMP and matrilysin, the only metalloproteinase which naturally lacks a C-terminal domain. Promatrilysin failed to bind the inhibitor. However, active matrilysin readily bound TIMP, forming a complex that resisted separation by gel filtration. When active matrilysin was forced to compete with truncated stromelysin for limiting amounts of TIMP, both enzymes appeared to complex the inhibitor with nearly equivalent efficacy. Indeed, active matrilysin exhibited a Ki for TIMP of 4.5 x 10(-9) M, essentially identical to that of truncated stromelysin. These data indicate that, as is true for collagenase, the C-terminal domain of stromelysin contributes significantly to its capacity to bind the physiologic inhibitor, TIMP. Furthermore, since stromelysin readily processes in vitro to a C-terminal truncated form, this enzyme species, as well as the full-length metalloproteinase matrilysin, may resist inhibition by TIMP in areas of active inflammation in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175679

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin.

Authors:  D C von Bredow; A E Cress; E W Howard; G T Bowden; R B Nagle
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

Review 2.  Computational sequence analysis of the tissue inhibitor of metalloproteinase family.

Authors:  D A Douglas; Y E Shi; Q A Sang
Journal:  J Protein Chem       Date:  1997-05

3.  Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers.

Authors:  Y Adachi; H Yamamoto; F Itoh; Y Hinoda; Y Okada; K Imai
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

4.  Enhanced cell surface expression of matrix metalloproteinases and their inhibitors, and tumor-induced host response in progression of human gastric carcinoma.

Authors:  Shohei Koyama
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

5.  Relation of matrilysin messenger RNA expression with invasive activity in human gastric cancer.

Authors:  A Senota; F Itoh; H Yamamoto; Y Adachi; Y Hinoda; K Imai
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

6.  Tissue inhibitor of metalloproteinase-1 moderates airway re-epithelialization by regulating matrilysin activity.

Authors:  Peter Chen; John K McGuire; Robert C Hackman; Kyoung-Hee Kim; Roy A Black; Kurt Poindexter; Wei Yan; Phillip Liu; Ann J Chen; William C Parks; David K Madtes
Journal:  Am J Pathol       Date:  2008-04-01       Impact factor: 4.307

Review 7.  Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.

Authors:  J Thomas Peterson
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

8.  Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme.

Authors:  I Halpert; U I Sires; J D Roby; S Potter-Perigo; T N Wight; S D Shapiro; H G Welgus; S A Wickline; W C Parks
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Matrix metalloproteinase protein expression profiles cannot distinguish between normal and early osteoarthritic synovial fluid.

Authors:  Bryan J Heard; Liam Martin; Jerome B Rattner; Cyril B Frank; David A Hart; Roman Krawetz
Journal:  BMC Musculoskelet Disord       Date:  2012-07-23       Impact factor: 2.362

10.  1alpha,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection.

Authors:  Anna Coussens; Peter M Timms; Barbara J Boucher; Timothy R Venton; Anthony T Ashcroft; Keira H Skolimowska; Sandra M Newton; Katalin A Wilkinson; Robert N Davidson; Christopher J Griffiths; Robert J Wilkinson; Adrian R Martineau
Journal:  Immunology       Date:  2008-12-18       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.